What is the appropriate management for iron‑deficiency anemia in an 82‑year‑old long‑term‑care resident with hemoglobin 8.3 g/dL, low serum iron, low transferrin saturation, borderline vitamin B12, and mild renal impairment (eGFR ≈ 56 mL/min/1.73 m²)?

Management of Iron Deficiency Anemia in an 82-Year-Old Long-Term Care Resident

This patient requires immediate oral iron supplementation (ferrous sulfate 200 mg once daily or every other day) while simultaneously pursuing gastrointestinal evaluation with upper endoscopy (including small bowel biopsies for celiac disease) and colonoscopy or CT colonography, with careful consideration of the risks and benefits given the patient's age, comorbidities, and performance status 1.

Diagnostic Confirmation

The laboratory values confirm severe iron deficiency anemia:

• Transferrin saturation of 4% (markedly below the <16-20% threshold) definitively establishes iron deficiency 2
• Serum iron of 18 is critically low
• Hemoglobin 8.3 g/dL represents significant anemia
• The borderline B12 of 213 (typically normal >200 pg/mL) is unlikely the primary cause but warrants monitoring
• The mild renal impairment (eGFR 56) is relevant but not severe enough to be the primary driver of this degree of anemia 1

In the context of mild CKD (stage 3a), iron deficiency is defined as transferrin saturation ≤20% with ferritin <100 μg/L, which this patient clearly meets 1, 3.

Immediate Treatment Strategy

Iron Replacement Therapy

Start with oral iron immediately—do not defer treatment while awaiting investigations 1. The most appropriate regimen for this 82-year-old is:

• Ferrous sulfate 200 mg once daily as first-line 4, 1
• If not tolerated, reduce to one tablet every other day, which is equally effective in elderly patients and significantly reduces adverse effects 1, 5
• Alternative preparations (ferrous fumarate or ferrous gluconate) if ferrous sulfate is not tolerated 4

Critical evidence: A 2005 study specifically in octogenarians demonstrated that low-dose iron (15 mg elemental iron daily) was as effective as higher doses (150 mg daily) in correcting anemia over 60 days, with significantly fewer gastrointestinal side effects 5. This is particularly relevant for long-term care residents who may have difficulty tolerating standard doses.

Monitoring Response

• Check hemoglobin at 4 weeks to confirm response (expect rise of approximately 2 g/dL) 2, 1
• Continue iron for 3 months after hemoglobin normalizes to replenish stores 4, 2, 1
• If no response after 3-4 weeks, consider intravenous iron or investigate for continued blood loss, malabsorption, or non-compliance 2

Gastrointestinal Investigation

The age of 82 years mandates serious consideration of GI pathology, particularly malignancy 2, 1. However, the approach must be individualized based on:

Risk-Benefit Assessment

The 2021 British Society of Gastroenterology guidelines specifically address this population: "The risks and benefits of invasive endoscopic and alternative investigation(s) are carefully considered in those with major comorbidities and/or limited performance status" 1.

Recommended Investigations

1. Upper endoscopy with duodenal biopsies 2, 1:

   • 2-3% of IDA patients have celiac disease, which is treatable 2
   • Upper GI pathology found in 30-50% of cases 2
   • Small bowel biopsies are mandatory even without symptoms 2

2. Lower GI evaluation 2, 1:

   • CT colonography may be more appropriate than colonoscopy for this elderly long-term care resident, as it avoids sedation risks and is better tolerated 1
   • Colonoscopy remains an option if the patient is fit enough
   • Dual pathology (upper and lower GI lesions) occurs in 10-15% of cases, so both upper and lower tract evaluation is needed unless a definitive cause is found 2

Special Considerations in This Patient

The mild renal impairment (eGFR 56) adds complexity 1:

• CKD itself contributes to anemia through multiple mechanisms (reduced erythropoietin, functional iron deficiency, chronic inflammation) 1
• However, CKD should not preclude GI investigation when iron deficiency is confirmed 1
• The severity of iron deficiency (transferrin saturation 4%) strongly suggests ongoing GI blood loss rather than CKD alone

Additional Diagnostic Considerations

Helicobacter pylori Testing

If initial endoscopy is negative or IDA persists/recurs, test for H. pylori by non-invasive methods and eradicate if present 4.

Medication Review

• Document use of NSAIDs, aspirin, or anticoagulants (common in long-term care facilities) 2
• These should not deter investigation but may contribute to blood loss 2

Borderline B12

The B12 level of 213 pg/mL is borderline. While not the primary cause of this microcytic anemia, consider:

• Monitoring B12 levels during treatment
• Supplementation if levels decline or if macrocytosis develops (suggesting combined deficiency) 2

When to Consider Intravenous Iron

Intravenous iron should be considered if 4, 1:

• Oral iron is not tolerated after trying reduced doses or alternative preparations
• No response to oral iron after 3-4 weeks
• Severe symptomatic anemia requiring rapid correction (though transfusion may be needed if symptomatic)
• Malabsorption is identified (e.g., celiac disease with severe villous atrophy)

Available IV preparations include iron sucrose (Venofer), ferric carboxymaltose (Ferinject), or iron dextran (Cosmofer), with appropriate monitoring for infusion reactions 4.

Common Pitfalls to Avoid

1. Do not delay iron therapy while awaiting investigations—this is explicitly contraindicated 1
2. Do not assume age alone explains the anemia—malignancy must be excluded 1
3. Do not attribute anemia solely to CKD when transferrin saturation is this low (4%)—GI blood loss is likely 1
4. Do not use standard high-dose iron regimens in elderly patients without first trying lower, better-tolerated doses 5
5. Do not forget duodenal biopsies during upper endoscopy—celiac disease is easily missed 2
6. Do not stop at finding one lesion—dual pathology is common, requiring complete evaluation 2

Follow-Up Strategy

• Hemoglobin and iron studies at 4 weeks, then monthly until normalized 1
• Continue iron for 3 months after correction 4, 2, 1
• Monitor at 3-month intervals for the first year, then annually 2
• Further investigation only if anemia recurs or fails to respond to treatment 2